Conference taking place on March 27-29, 2025 in New Orleans -- -- CAGLA NeauxCancer Conference is a leading global forum in ...

Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.

On Monday, activist Idelisa Diasniurka Salcedo Verdecia voiced her concerns regarding the chemotherapy administered to young ...

Positive updates continue to emerge from Nicklaus Children's Hospital in Miami, where young Damir Ortiz, a Cuban child in ...

After months of waiting, a young boy from Cuba battling a medical condition is getting a second chance at life after he and ...

Researchers have found in a nonrandomised pilot trial that selumetinib showed a reduction in cutaneous neurofibromatosis ...

RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according ...

Hereditary predisposition is a relevant cause of cancer in children and adolescents. At least 10% of all pediatric tumors are ...

SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See why SWTX is a good speculative “Buy”.

Discover a study that used the Skindex-29 assessment to evaluate emotional wellbeing during selumetinib cycles.

BACKGROUND: Plexiform neurofibromas represent a common neoplasia of type 1 neurofibromatosis in which neurofibromas arise from multiple nerves involving connective tissue and skin and rarely affect ...